An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy

Trial Profile

An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Acronyms BRITE
  • Sponsors UCB
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 07 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 28 Apr 2017 lts of post hoc pooled analysis from long-term follow-up studies (NCT00175916, NCT00150800, NCT01339559) presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top